Slenyto® is the first and only pharmacotherapy that is approved for the treatment of insomnia in children with Autism Spectrum Disorder (ASD) and/or Smith-Magenis Syndrome (SMS). Slenyto® is a prolonged-release melatonin minitablet developed specifically for the treatment of insomnia in these children, addressing their specific needs.
Insomnia & ASD
50-80% of children with ASD suffer from insomnia, much more than typically developed children.
Sleep deficit exacerbates cognitive and behavioural problems in ASD children and adolescent, and is also challenging for their families.